Revolution Medicines, Inc.

RVMD Healthcare Biotechnology

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022. In the quarter to June 2026, EPS fell 133.6%, free cash flow fell 70.0% and total debt rose 322.7%, each against the same quarter a year earlier.

177.96 11.30 −5.97%
Market cap
$40.6B
P/E
0.0×
Fwd P/E
−11.9×
Dividend yield
—
F-score
4/9
Altman Z
7.73
Beneish M
−4.29
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(79.09%) (76.67%) (58.07%) (60.76%)

+8 more TTM periods

ROA
(52.37%) (59.39%) (46.06%) (47.87%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(47.68%) (80.23%) (62.23%) (54.45%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(5.84) (5.41) (4.81) (4.11)
Free Cash Flow
(1,232.13) (1,071.73) (913.73) (777.08)
Capital Expenditures
(9.10) (14.26) (15.99) (15.29)
Other line items
Cash ROIC
(16.25%) (29.05%) (23.28%) (20.53%)
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Interest Coverage
(27.42) (38.07) (33.61) (30.74)
Operating CF/Net income
0.69 0.77 0.79 0.79
Depreciation/Fixed assets
0.01 (0.12) (0.34) (0.51)
Capex/Depreciation
(36.69) 3.69 1.42 0.91
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(5.80) (5.34) (4.72) (4.03)
Capex per Share
(0.04) (0.07) (0.08) (0.08)
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates